ADMA Biologics, Inc. ADMA
12.67 USD -0.12 (-0.94%)
At closeNov 10, 2026, 7:07 PM EST
12.80 +0.13 +1.03%
After hours · Nov 10, 7:07 PM ET
12.55 Day range 12.95
7.21 52-week range 20.46
- YTD
- -30.54%
- 1 year
- -13.87%
News
zacks.com Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a…
zacks.com Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
benzinga.com Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed as Nasdaq fell over 3%, while Motorola Solutions and other companies surged on strong earnings and raised guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13 Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.
benzinga.com ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why ADMA Biologics shares surge after Q3 earnings growth as the company raises 2026 profit guidance.
seekingalpha.com ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
zacks.com Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
marketbeat.com ADMA Biologics Q3 Earnings Call Highlights ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive…
benzinga.com ADMA Biologics Q3 2026 Earnings Call Transcript ADMA Biologics (NASDAQ:ADMA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is a 43.75 percent increase over earnings of $0.16…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
globenewswire.com ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37%…
zacks.com Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.
zacks.com Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
zacks.com Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
globenewswire.com ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 RAMSEY, N.J. and BOCA RATON, Fla.
zacks.com Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.
globenewswire.com ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
zacks.com Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
defenseworld.net ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
zacks.com Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
zacks.com ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
defenseworld.net ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from Analysts Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports.…
zacks.com Here's Why Adma Biologics (ADMA) Fell More Than Broader Market In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
zacks.com Why Adma Biologics (ADMA) Dipped More Than Broader Market Today Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
zacks.com Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
benzinga.com ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.- benzinga.com ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of…
benzinga.com Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17 Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.
benzinga.com Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.- benzinga.com Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18 Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.- benzinga.com Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20 Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.
benzinga.com Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
- benzinga.com ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14…
benzinga.com ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.Additionally, the approval provides for a revision of ASCENIV's…
benzinga.com Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21 Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend. Other gains: AGX 35.5%, MSC 24.5%, ADMA 13%, SGML 12.2%, KOD 10.5%, TBN 9.9%, METC 8.8%, U 8.3%,…
benzinga.com ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand ADMA Biologics stock rebounds premarket after a 30% drop tied to short seller claims, as the company defends demand and financial reporting.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session